Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

Journal of hepatology - 1 Oct 2013

Ogawa Eiichi, Furusyo Norihiro, Nakamuta Makoto, Kajiwara Eiji, Nomura Hideyuki, Dohmen Kazufumi, Takahashi Kazuhiro, Satoh Takeaki, Azuma Koichi, Kawano Akira, Tanabe Yuichi, Kotoh Kazuhiro, Shimoda Shinji, Hayashi Jun

Abstract excerpt

BACKGROUND & AIMS: Anemia is a common adverse effect of telaprevir (TVR) in combination with pegylated interferon (PegIFN)α and ribavirin (RBV) therapy. It occurs at a higher incidence with the TVR relative to PegIFNα and RBV alone. We herein evaluate the baseline and on-treatment predictors of the development of severe anemia by chronic hepatitis C virus (HCV) patients receiving TVR-based triple therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Pyrophosphatases

Share to Ribavirin

Source

Identifiers

PMID: 23707372
DOI: 10.1016/j.jhep.2013.05.017

Genes

ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.PMID 23707372Read ↗

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.Semantic proximity Read ↗

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Semantic proximity Read ↗

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

Pharmacogenetics of ribavirin-induced anemia in HCV patients.Semantic proximity Read ↗

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.Semantic proximity Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.Semantic proximity Read ↗

Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.Semantic proximity Read ↗

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.Semantic proximity Read ↗

Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.